97 results for "Elliott, Perry M."
Showing 1–20 · 2.34 seconds · RSS
-
Journal Article Full text
The heart in Anderson‐Fabry disease and other lysosomal storage disorders
-
Journal Article Full text
Arrhythmogenic Cardiomyopathy: A Disease or Merely a Phenotype?
Arrhythmogenic cardiomyopathy (AC) is a clinical entity that has evolved conceptually over the past 30 years. Advances in cardiac imaging and the introduction of genetics into everyday practice have revealed that AC comprises multiple phenotypes that are dependent on genetic or acquired factors. In…
-
Journal Article Full text
Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice
Pathogenic variation in genes encoding proteins of the cardiac sarcomere is responsible for 30%–40% of cases of hypertrophic cardiomyopathy. The main clinical utility of genetic testing is to provide diagnostic confirmation and facilitation of family screening. It also assists in the detection of…
-
Journal Article Full text
The distribution of hypertrophy in anderson fabry disease
Also available at: PubMed Central
-
Journal Article Full text
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten was developed to target…
-
Journal Article Full text
Is QT Dispersion Associated with Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy?
QT dispersion is significantly greater in patients with hypertrophic cardiomyopathy (HCM) than that in healthy subjects. Few data exist regarding the prognostic value of QT dispersion in HCM. In this study, we retrospectively investigated the association between QT dispersion and sudden cardiac…
-
Journal Article Full text
Right ventricular function is a predictor for sustained ventricular tachycardia requiring anti-tachycardic pacing in arrhythmogenic ventricular cardiomyopathy: insight into transvenous vs. subcutaneous implantable cardioverter defibrillator insertion
AIMS: Arrhythmogenic right ventricular cardiomyopathy (ARVC) patients develop ventricular arrhythmias (VAs) responsive to anti-tachycardia pacing (ATP). However, VA episodes have not been characterized in accordance with the device therapy, and with the emergence of the subcutaneous implantable…
-
Journal Article Full text
Heart Rate Recovery in Patients With Hypertrophic Cardiomyopathy
Recovery in heart rate (HR) after exercise is a measure of autonomic function and a prognostic indicator in cardiovascular disease. The aim of this study was to characterize heart rate recovery (HRR) and to determine its relation to cardiac function and morphology in patients with hypertrophic…
-
Journal Article Full text
The use of multiparametric CMR to predict impaired exercise capacity in hypertrophic cardiomyopathy
Also available at: PubMed Central
-
Journal Article Full text
Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis
-
Journal Article Full text
Prevalence of transthyretin cardiac amyloidosis in patients with high-degree AV block
OBJECTIVE: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative cardiac disorder caused by deposition of wild type or mutated transthyretin. As ATTR-CM is associated with conduction disease, we sought to determine its prevalence in patients with idiopathic high-degree atrioventricular…
-
Journal Article Full text
Prevalence of Hypertrophic Cardiomyopathy in the UK Biobank Population
This cohort study examines the prevalence of hypertrophic cardiomyopathy in the UK Biobank population.
-
Journal Article Full text
Performance of the PRIMaCY sudden death risk prediction model for childhood hypertrophic cardiomyopathy: implications for implantable cardioverter-defibrillator decision-making
AIMS: The validated HCM Risk-Kids model provides accurate individualized estimates of sudden cardiac death risk in children with hypertrophic cardiomyopathy (HCM). A second validated model, PRIMaCY, also provides individualized estimates of risk, but its performance and clinical impact has not been…
-
Journal Article Full text
Myosin inhibitors for treatment of hypertrophic cardiomyopathy
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: PRIMARY OBJECTIVE: To assess the effects of myosin inhibitors compared to usual care or placebo on exercise capacity, need for septal reduction therapy, and all‐cause mortality in people with hypertrophic…
-
Journal Article Full text
Clinical utility gene card for: hypertrophic cardiomyopathy (type 1–14)
-
Journal Article Full text
Isolated aortic root dilation in homocystinuria
BACKGROUND: Vascular complications in homocystinuria have been known for many years, but there have been no reports to date on involvement of the ascending aorta. METHODS: We conducted a cross-sectional study of patients with homocystinuria, known to a single metabolic centre, and evaluated in 2016…